Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Midazolam and Dexmedetomidine Affect Neuroglioma and Lung Carcinoma Cell Biology In Vitro and In Vivo.

Wang C, Datoo T, Zhao H, Wu L, Date A, Jiang C, Sanders RD, Wang G, Bevan C, Ma D.

Anesthesiology. 2018 Aug 29. doi: 10.1097/ALN.0000000000002401. [Epub ahead of print]

PMID:
30157038
2.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527. [Epub ahead of print]

PMID:
30141729
3.

Analytical methods impact estimates of trichloroethylene's glutathione conjugation and risk assessment.

Zhang F, Marty S, Budinsky R, Bartels M, Pottenger LH, Bus J, Bevan C, Erskine T, Clark A, Holzheuer B, Markham D.

Toxicol Lett. 2018 Oct 15;296:82-94. doi: 10.1016/j.toxlet.2018.07.006. Epub 2018 Aug 3.

PMID:
30081224
4.

Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo.

Dart DA, Kandil S, Tommasini-Ghelfi S, Serrano de Almeida G, Bevan CL, Jiang W, Westwell AD.

Mol Cancer Ther. 2018 Sep;17(9):1846-1858. doi: 10.1158/1535-7163.MCT-18-0037. Epub 2018 Jun 12.

PMID:
29895558
5.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

6.

Light-triggered enzymatic reactions in nested vesicle reactors.

Hindley JW, Elani Y, McGilvery CM, Ali S, Bevan CL, Law RV, Ces O.

Nat Commun. 2018 Mar 15;9(1):1093. doi: 10.1038/s41467-018-03491-7.

7.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407. [Epub ahead of print]

PMID:
29310490
8.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.

PMID:
29258679
9.

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Büdingen HC.

JCI Insight. 2017 Nov 16;2(22). pii: 92724. doi: 10.1172/jci.insight.92724. [Epub ahead of print]

10.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.

Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.

11.

Lipid profiling of complex biological mixtures by liquid chromatography/mass spectrometry using a novel scanning quadrupole data-independent acquisition strategy.

Gethings LA, Richardson K, Wildgoose J, Lennon S, Jarvis S, Bevan CL, Vissers JPC, Langridge JI.

Rapid Commun Mass Spectrom. 2017 Oct 15;31(19):1599-1606. doi: 10.1002/rcm.7941.

PMID:
28703389
12.

The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells.

Koushyar S, Economides G, Zaat S, Jiang W, Bevan CL, Dart DA.

Oncogenesis. 2017 May 15;6(5):e333. doi: 10.1038/oncsis.2017.32.

13.

Onset of secondary progressive MS after long-term rituximab therapy - a case report.

von Büdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL.

Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.

14.

A novel role for GSK3β as a modulator of Drosha microprocessor activity and MicroRNA biogenesis.

Fletcher CE, Godfrey JD, Shibakawa A, Bushell M, Bevan CL.

Nucleic Acids Res. 2016 Oct 23. pii: gkw938. [Epub ahead of print]

15.

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM.

J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.

16.

WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer.

Leach DA, Powell SM, Bevan CL.

Endocr Relat Cancer. 2016 Nov;23(11):T85-T108. Epub 2016 Sep 19. Review.

17.

Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.

Leach DA, Panagopoulos V, Nash C, Bevan C, Thomson AA, Selth LA, Buchanan G.

Mol Cell Endocrinol. 2017 Jan 5;439:261-272. doi: 10.1016/j.mce.2016.09.010. Epub 2016 Sep 12.

18.

WOMEN IN CANCER PROFILE: A gender agenda?

Bevan CL.

Endocr Relat Cancer. 2016 Nov;23(11):P5-P8. Epub 2016 Sep 6. No abstract available.

19.

Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis.

Metcalf GA, Shibakawa A, Patel H, Sita-Lumsden A, Zivi A, Rama N, Bevan CL, Ladame S.

Anal Chem. 2016 Aug 16;88(16):8091-8. doi: 10.1021/acs.analchem.6b01594. Epub 2016 Aug 7.

20.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

21.

Advances in genetics: widening our understanding of prostate cancer.

Pine AC, Fioretti FF, Brooke GN, Bevan CL.

F1000Res. 2016 Jun 27;5. pii: F1000 Faculty Rev-1512. doi: 10.12688/f1000research.8019.1. eCollection 2016. Review.

22.

In Vivo Imaging of Nuclear Receptor Transcriptional Activity.

Dart DA, Bevan CL.

Methods Mol Biol. 2016;1443:203-17. doi: 10.1007/978-1-4939-3724-0_13.

PMID:
27246342
23.

Fulminant Demyelinating Diseases of the Central Nervous System.

Bevan CJ, Cree BA.

Semin Neurol. 2015 Dec;35(6):656-66. doi: 10.1055/s-0035-1564682. Epub 2015 Nov 23. Review.

PMID:
26595866
24.

Research priorities for stillbirth: process overview and results from UK Stillbirth Priority Setting Partnership.

Heazell AE, Whitworth MK, Whitcombe J, Glover SW, Bevan C, Brewin J, Calderwood C, Canter A, Jessop F, Johnson G, Martin I, Metcalf L.

Ultrasound Obstet Gynecol. 2015 Dec;46(6):641-7. doi: 10.1002/uog.15738. No abstract available.

25.

Less invasive investigation of perinatal death.

Arthurs OJ, Bevan C, Sebire NJ.

BMJ. 2015 Jul 8;351:h3598. doi: 10.1136/bmj.h3598. No abstract available.

PMID:
26155793
26.

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG.

JAMA Neurol. 2015 Aug;72(8):897-904. doi: 10.1001/jamaneurol.2015.0993.

27.

Therapeutic management of severe relapses in multiple sclerosis.

Bevan C, Gelfand JM.

Curr Treat Options Neurol. 2015 Apr;17(4):345. doi: 10.1007/s11940-015-0345-6.

PMID:
25794777
28.

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL.

Mol Cell Proteomics. 2015 May;14(5):1201-16. doi: 10.1074/mcp.M113.036764. Epub 2015 Feb 18.

29.

Establishing the research priorities of paediatric emergency medicine clinicians in the UK and Ireland.

Hartshorn S, O'Sullivan R, Maconochie IK, Bevan C, Cleugh F, Lyttle MD; Paediatric Emergency Research in the UK and Ireland (PERUKI).

Emerg Med J. 2015 Nov;32(11):864-8. doi: 10.1136/emermed-2014-204484. Epub 2015 Feb 12.

30.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

31.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

32.

Experiences with maternal and perinatal death reviews in the UK--the MBRRACE-UK programme.

Kurinczuk JJ, Draper ES, Field DJ, Bevan C, Brocklehurst P, Gray R, Kenyon S, Manktelow BN, Neilson JP, Redshaw M, Scott J, Shakespeare J, Smith LK, Knight M; MBRRACE-UK (Mothers and Babies: Reducing Risk through Audit and Confidential Enquiries across the UK).

BJOG. 2014 Sep;121 Suppl 4:41-6. doi: 10.1111/1471-0528.12820.

33.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
34.

Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG.

Ann Neurol. 2014 Oct;76(4):568-80. doi: 10.1002/ana.24241. Epub 2014 Aug 21.

35.

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination.

Huang H, Benzonana LL, Zhao H, Watts HR, Perry NJ, Bevan C, Brown R, Ma D.

Br J Cancer. 2014 Sep 23;111(7):1338-49. doi: 10.1038/bjc.2014.426. Epub 2014 Jul 29.

36.

Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers.

Fletcher CE, Dart DA, Bevan CL.

Endocr Relat Cancer. 2014 Oct;21(5):R409-29. doi: 10.1530/ERC-14-0208. Epub 2014 Jul 25. Review.

37.

Revising the role of the androgen receptor in breast cancer.

Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN.

J Mol Endocrinol. 2014 Jun;52(3):R257-65. doi: 10.1530/JME-14-0030. Epub 2014 Apr 16. Review.

PMID:
24740738
38.

Engineered repressors are potent inhibitors of androgen receptor activity.

Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL.

Oncotarget. 2014 Feb 28;5(4):959-69.

39.

Pediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research.

Lyttle MD, O'Sullivan R, Hartshorn S, Bevan C, Cleugh F, Maconochie I; PERUKI.

Arch Dis Child. 2014 Jun;99(6):602-3. doi: 10.1136/archdischild-2013-304998. Epub 2014 Mar 10. No abstract available.

PMID:
24615624
40.

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

Bevan CJ, Cree BA.

JAMA Neurol. 2014 Mar;71(3):269-70. doi: 10.1001/jamaneurol.2013.5486. No abstract available. Erratum in: JAMA Neurol. 2014 Jun;71(6):803.

PMID:
24395449
41.

Complications in pediatric scoliosis surgery.

Sullivan DJ, Primhak RA, Bevan C, Breakwell LM, Humphreys N.

Paediatr Anaesth. 2014 Apr;24(4):406-11. doi: 10.1111/pan.12338. Epub 2013 Dec 24.

PMID:
24372904
42.

Nerve blocks for initial pain management of femoral fractures in children.

Black KJ, Bevan CA, Murphy NG, Howard JJ.

Cochrane Database Syst Rev. 2013 Dec 17;(12):CD009587. doi: 10.1002/14651858.CD009587.pub2. Review.

PMID:
24343768
43.

The full spectrum of handlebar injuries in children: a decade of experience.

Nataraja RM, Palmer CS, Arul GS, Bevan C, Crameri J.

Injury. 2014 Apr;45(4):684-9. doi: 10.1016/j.injury.2013.07.022. Epub 2013 Dec 8.

PMID:
24321415
44.

Circulating nucleic acids as biomarkers of prostate cancer.

Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL.

Biomark Med. 2013 Dec;7(6):867-77. doi: 10.2217/bmm.13.104. Review.

PMID:
24266819
45.

How to use capillary refill time.

King D, Morton R, Bevan C.

Arch Dis Child Educ Pract Ed. 2014 Jun;99(3):111-6. doi: 10.1136/archdischild-2013-305198. Epub 2013 Nov 13. Review. No abstract available.

PMID:
24227793
46.

A survey of frameworks for best practices in weight-of-evidence analyses.

Rhomberg LR, Goodman JE, Bailey LA, Prueitt RL, Beck NB, Bevan C, Honeycutt M, Kaminski NE, Paoli G, Pottenger LH, Scherer RW, Wise KC, Becker RA.

Crit Rev Toxicol. 2013 Oct;43(9):753-84. doi: 10.3109/10408444.2013.832727. Review.

PMID:
24040995
47.

Peripheral T-cell lymphoma emerging in a patient with aggressive polymyositis: molecular evidence for neoplastic transformation of an oligoclonal T-cell infiltrate.

Tsankova NM, Bevan C, Jobanputra V, Ko YC, Mayer EW, Lefkowitch JH, Mansukhani M, Rowland LP, Bhagat G, Tanji K.

Acta Neuropathol. 2013 Oct;126(4):595-601. doi: 10.1007/s00401-013-1164-z. Epub 2013 Aug 13.

PMID:
23942639
48.

Visualising androgen receptor activity in male and female mice.

Dart DA, Waxman J, Aboagye EO, Bevan CL.

PLoS One. 2013 Aug 7;8(8):e71694. doi: 10.1371/journal.pone.0071694. Print 2013.

49.

Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer.

Frampton AE, Fletcher CE, Gall TM, Castellano L, Bevan CL, Stebbing J, Krell J.

Expert Rev Mol Diagn. 2013 Jun;13(5):425-30. doi: 10.1586/erm.13.31.

PMID:
23782250
50.

Circulating microRNAs as potential new biomarkers for prostate cancer.

Sita-Lumsden A, Dart DA, Waxman J, Bevan CL.

Br J Cancer. 2013 May 28;108(10):1925-30. doi: 10.1038/bjc.2013.192. Epub 2013 Apr 30. Review.

Supplemental Content

Support Center